- Home
- MIRM vs BYD Comparison
MIRM vs BYD Comparison
Compare MIRM & BYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | BYD |
|---|---|---|
| Founded | 2018 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MIRM | BYD |
|---|---|---|
| Price | $107.23 | $84.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | ★ $119.85 | $90.82 |
| AVG Volume (30 Days) | 637.7K | ★ 975.6K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | 74.59 | ★ 264.46 |
| EPS | N/A | ★ 1.37 |
| Revenue | $19,138,000.00 | ★ $2,626,730,000.00 |
| Revenue This Year | $26.22 | $1.71 |
| Revenue Next Year | $22.04 | $2.74 |
| P/E Ratio | ★ N/A | $61.48 |
| Revenue Growth | N/A | ★ 9.41 |
| 52 Week Low | $47.89 | $76.33 |
| 52 Week High | $114.99 | $89.96 |
Technical Indicators
Market Signals| Indicator | MIRM | BYD |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 48.98 |
| Support Level | $87.93 | $84.09 |
| Resistance Level | $107.51 | $85.00 |
| Average True Range (ATR) | 4.13 | 2.36 |
| MACD | 1.17 | -0.14 |
| Stochastic Oscillator | 96.61 | 31.48 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.